[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=69a35768110dc32382e8bba3ed478e351a3681491b5866076ebea0792389b207",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748622660,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 134940020,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=69a35768110dc32382e8bba3ed478e351a3681491b5866076ebea0792389b207"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates",
    "summary": "LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.",
    "url": "https://finnhub.io/api/news?id=8f13ce21770fcdb0b591ca5e8e792d3efae92641786efb67e770e4074d09557e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748613600,
      "headline": "Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates",
      "id": 134905237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.",
      "url": "https://finnhub.io/api/news?id=8f13ce21770fcdb0b591ca5e8e792d3efae92641786efb67e770e4074d09557e"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Opportunities Fund Q1 2025 Commentary",
    "summary": "abrdn Healthcare Opportunities Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=b711ffff6bce49ff9d5022585a2f181130d7472e23b9296d94389bf9ea6cd4ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748604900,
      "headline": "abrdn Healthcare Opportunities Fund Q1 2025 Commentary",
      "id": 134904305,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b711ffff6bce49ff9d5022585a2f181130d7472e23b9296d94389bf9ea6cd4ef"
    }
  },
  {
    "ts": null,
    "headline": "3 American Growth Giants to Invest in for the Long Haul",
    "summary": "All generate strong profit margins, which can help them weather a challenging economy.  Many of the best growth stocks in the world are based out of the U.S. This is the land of both opportunity and innovation.  Warren Buffett has always been bullish on betting on the U.S. because he's a big believer in American business.",
    "url": "https://finnhub.io/api/news?id=9b98a4702eb5fe95099a9bcc4f371b7ce5da1d95359402ad7e28e8dbbdf3c104",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748604600,
      "headline": "3 American Growth Giants to Invest in for the Long Haul",
      "id": 134898456,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "All generate strong profit margins, which can help them weather a challenging economy.  Many of the best growth stocks in the world are based out of the U.S. This is the land of both opportunity and innovation.  Warren Buffett has always been bullish on betting on the U.S. because he's a big believer in American business.",
      "url": "https://finnhub.io/api/news?id=9b98a4702eb5fe95099a9bcc4f371b7ce5da1d95359402ad7e28e8dbbdf3c104"
    }
  },
  {
    "ts": null,
    "headline": "5 Alpha Generating Monsters",
    "summary": "Any stock can generate alpha, but doing it consistently is rare. Learn how valuation & growth metrics play a key role in identifying winners.",
    "url": "https://finnhub.io/api/news?id=ca1d52f795e3a730d4ef739bfd0545b28a3ea11a0544ae7ea771eea6f3082872",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748601176,
      "headline": "5 Alpha Generating Monsters",
      "id": 134901990,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357925578/image_1357925578.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Any stock can generate alpha, but doing it consistently is rare. Learn how valuation & growth metrics play a key role in identifying winners.",
      "url": "https://finnhub.io/api/news?id=ca1d52f795e3a730d4ef739bfd0545b28a3ea11a0544ae7ea771eea6f3082872"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: to present data on six treatments",
    "summary": "Eli Lilly and Company announces the presentation of clinical results for six molecules in development, including orforglipron, insulin efsitora alfa, tirzepatide , retatrutide, eloralintide and...",
    "url": "https://finnhub.io/api/news?id=0adacca715946ff50f5c9360f70221dfc4f5f0b3c0739dc0d293e6c71670887a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748599600,
      "headline": "Eli Lilly: to present data on six treatments",
      "id": 134899557,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company announces the presentation of clinical results for six molecules in development, including orforglipron, insulin efsitora alfa, tirzepatide , retatrutide, eloralintide and...",
      "url": "https://finnhub.io/api/news?id=0adacca715946ff50f5c9360f70221dfc4f5f0b3c0739dc0d293e6c71670887a"
    }
  },
  {
    "ts": null,
    "headline": "How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race",
    "summary": "Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.",
    "url": "https://finnhub.io/api/news?id=d26daf789ffc16bb70828f2b60efaf5a6e6bd9412aea6f10f557aba03bac55cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748595600,
      "headline": "How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race",
      "id": 134895774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.",
      "url": "https://finnhub.io/api/news?id=d26daf789ffc16bb70828f2b60efaf5a6e6bd9412aea6f10f557aba03bac55cc"
    }
  }
]